Product Description
Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27387373/)
Mechanisms of Action: Immunomodulator, TLR7 Agonist, TLR8 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Spain, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Basal Cell Carcinoma|Cervical Cancer|Hepatitis B|Keratosis, Actinic|Papilloma
Phase 1: Glioma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06305910 |
Phase I Trial | P1 |
Recruiting |
Glioma |
2025-09-15 |
67% |
2024-06-26 |
Primary Endpoints|Treatments |
NCT07251413 |
CEMIQUID | P2 |
Recruiting |
Basal Cell Carcinoma |
2028-12-01 |
12% |
2025-11-27 |
|
NCT06686043 |
HPV-VIM | P2 |
Recruiting |
Cervical Cancer|Papilloma |
2026-08-23 |
2024-11-14 |
Primary Endpoints|Treatments |
|
2024-514605-61-00 |
2020PI198 | P2 |
Not yet recruiting |
Hepatitis B |
2026-08-07 |
2025-05-02 |
Treatments |
|
2024-515667-60-00 |
OJ-KDC01 | P2 |
Recruiting |
Keratosis, Actinic |
2025-08-31 |
2025-05-02 |
Treatments |
|
2019-002285-12 |
2019-002285-12 | P2 |
Active, not recruiting |
Keratosis, Actinic |
None |
2022-03-13 |
Treatments |